clinical trial · NCT04058756
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Advanced Solid TumorsPDR001
brief summary
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
started
Oct 30, 2019
primary completion
Apr 30, 2030
completion
Apr 30, 2030
last updated
Oct 7, 2025
official title
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol